Advertisement
Singapore markets close in 6 hours 36 minutes
  • Straits Times Index

    3,131.32
    -10.53 (-0.34%)
     
  • Nikkei

    39,873.40
    +707.21 (+1.81%)
     
  • Hang Seng

    16,486.82
    -24.62 (-0.15%)
     
  • FTSE 100

    7,630.02
    +5.04 (+0.07%)
     
  • Bitcoin USD

    61,028.05
    -152.89 (-0.25%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • S&P 500

    5,096.27
    +26.51 (+0.52%)
     
  • Dow

    38,996.39
    +47.37 (+0.12%)
     
  • Nasdaq

    16,091.92
    +144.18 (+0.90%)
     
  • Gold

    2,053.40
    -1.30 (-0.06%)
     
  • Crude Oil

    78.51
    +0.25 (+0.32%)
     
  • 10-Yr Bond

    4.2520
    -0.0220 (-0.51%)
     
  • FTSE Bursa Malaysia

    1,552.36
    +0.92 (+0.06%)
     
  • Jakarta Composite Index

    7,318.58
    +2.47 (+0.03%)
     
  • PSE Index

    6,945.69
    +0.98 (+0.01%)
     

The Zacks Analyst Blog Highlights PepsiCo, Verizon Communications, Sanofi, Vale and Paychex

For Immediate Release

Chicago, IL – January 20, 2023 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: PepsiCo, Inc. PEP, Verizon Communications Inc. VZ, Sanofi SNY, Vale S.A. VALE and Paychex, Inc. PAYX.

Here are highlights from Thursday’s Analyst Blog:

Top Research Reports for PepsiCo, Verizon and Sanofi

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including PepsiCo, Inc., Verizon Communications Inc. and Sanofi. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

You can see all of today's research reports here >>>

Shares of PepsiCo have modestly lagged rival Coca Cola over the past year (-2.3% vs. -1.1%), but they have done notably better than the Zacks Consumer Staples sector (down -5.7%) and the S&P 500 index (down -14.7%). The company is undoubtedly faced with near-term margin pressures on account of higher expenses, but it is nevertheless well positioned to profitably operate in this environment.

PepsiCo's revenues and earnings beat the Zacks Consensus Estimate and improved year over year in the third quarter. This marked the 17th straight quarter of sales beat. The company benefits from the resilience and strength of global beverage and convenient food businesses.

It expects to benefit by delivering convenience, variety and value proposition to customers through its brands. It raised its revenue view for 2022.

(You can read the full research report on PepsiCo here >>>)

Shares of Verizon Communications have underperformed the Zacks Wireless National industry over the past year (-25.3% vs. -11.7%). The company reiterated its soft guidance for 2022 due a to challenging macroeconomic environment. An intensely competitive market and hefty expenses on promotions and lucrative discounts to attract customers are likely to hurt profitability. Spectrum crunch with a saturated wireless market is another headwind.

However, Verizon plans to accelerate the availability of the 5G Ultra Wideband network with C-Band deployment, focusing on 5G mobility, nationwide broadband, mobile edge compute and business solutions. It is offering various mix-and-match pricing in both wireless and home broadband plans.

Verizon is also aggressively expanding its fiber optics network to support 4G LTE, 5G wireless standards and wireline connections. Customer-focused planning, disciplined engineering and continued network upgrades will likely augment its market position.

(You can read the full research report on Verizon Communications here >>>)

Shares of Sanofi have underperformed the Zacks Large Cap Pharmaceuticals industry over the past year (-5.6% vs. +13.2%). The company is facing headwinds which includes weak performance of diabetes drugs and recent negative pipeline developments. Shares have underperformed the industry this year so far.

However, Sanofi's Specialty Care unit is on a strong footing, particularly with the regular label expansion of Dupixent. Dupixent has become the key top-line driver for Sanofi. With outside U.S. revenues accelerating and multiple approvals for new indications, its sales are expected to be higher. Sanofi possesses a leading vaccine portfolio, which has become the primary top-line driver.

Its R&D pipeline is strong. Several data read-outs are expected in 2023. Sanofi's Consumer unit is delivering above-market sales growth. It has also launched several new drugs in the past couple of years and is expanding its pipeline through M&A deals.

(You can read the full research report on Sanofi here >>>)

Other noteworthy reports we are featuring today include Vale S.A. and Paychex, Inc..

Why Haven't You Looked at Zacks' Top Stocks?

Our 5 best-performing strategies have blown away the S&P's impressive +28.8% gain in 2021. Amazingly, they soared +40.3%, +48.2%, +67.6%, +94.4%, and +95.3%. Today you can access their live picks without cost or obligation.

See Stocks Free >>

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

support@zacks.com                       

https://www.zacks.com

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Sanofi (SNY) : Free Stock Analysis Report

Paychex, Inc. (PAYX) : Free Stock Analysis Report

Verizon Communications Inc. (VZ) : Free Stock Analysis Report

VALE S.A. (VALE) : Free Stock Analysis Report

PepsiCo, Inc. (PEP) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research